Jove
Visualize
Contact Us

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Nanoliposomal Ceramide Prevents In Vivo Growth Of Hepatocellular Carcinoma.
  1. Home
  3. Nanoliposomal Ceramide Prevents In Vivo Growth Of Hepatocellular Carcinoma.

Related Experiment Video

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.

Hephzibah Rani S Tagaram1, Nicole A Divittore, Brian M Barth

  • 1Departments of Pharmacology and of Cellular and Molecular Physiology, Hershey, PA 17033-0858, USA.

Gut
|January 4, 2011

View abstract on PubMed

Summary
This summary is machine-generated.

Nanoliposomal C6-ceramide effectively treats hepatocellular carcinoma (HCC) models by inducing cancer cell death and blocking tumor growth. This novel nanoliposomal ceramide shows promise as an antineoplastic agent for HCC.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

  • Oncology
  • Nanomedicine
  • Cancer Biology

Background:

  • Hepatocellular carcinoma (HCC) presents a growing global health challenge with poor patient survival rates.
  • HCC is characterized by aggressive, metastatic behavior and resistance to conventional therapies.
  • Developing novel antineoplastic agents is crucial for improving HCC treatment outcomes.

Purpose of the Study:

  • To investigate the efficacy of nanoliposomal C6-ceramide as an antineoplastic agent.
  • To evaluate its effects in both in vitro and in vivo models of human HCC.

Main Methods:

  • In vitro studies assessed nanoliposomal C6-ceramide's effects on SK-HEP-1 cells (viability, apoptosis, cell cycle, AKT phosphorylation).
  • In vivo studies involved subcutaneous implantation of SK-HEP-1 cells in nude mice, followed by systemic nanoliposomal C6-ceramide administration.
  • Tumor growth, vascularization, proliferation, apoptosis, and signaling pathways were analyzed post-treatment.

    • Main Results:

    • Nanoliposomal C6-ceramide induced apoptosis and G2 cell cycle arrest in vitro, with decreased AKT phosphorylation.
    • In vivo, treatment reduced tumor vascularization and proliferation while increasing apoptosis.
    • Nanoliposomal C6-ceramide administration effectively blocked tumor growth in the HCC mouse model.

    Conclusions:

    • Nanoliposomal C6-ceramide demonstrates significant antineoplastic activity against human HCC.
    • The agent effectively induces apoptosis and inhibits tumor growth in both in vitro and in vivo settings.
    • Nanoliposomal ceramide represents a promising therapeutic strategy for hepatocellular carcinoma.